Orchard Therapeutics

orchard-tx.com

Orchard Therapeutics is a fully integrated commercial-stage company dedicated to treating patients with rare diseases through innovative gene therapies. Their portfolio includes autologous ex vivo gene therapy programs that have shown sustained clinical benefits in over 150 patients across five disease areas, including Strimvelis®, the first autologous ex vivo gene therapy approved by the EMA in 2016. They are advancing registrational studies in MLD, WAS, and ADA-SCID, along with clinical programs in X-CGD and beta-thalassemia, supported by partnerships with leading institutions in gene therapy.